GIGeoffrey S. Ibbott

Geoffrey S. Ibbott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Geoffrey S. Ibbott has a total of 270 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    3D dosimetry of proton beams and influences on response

    by G. Ibbott, M. Carroll

    Proton beams offer the ability to conform dose distributions exquisitely to target volumes, allowing radiation oncologists to avoid exceeding tolerance doses to sensitive normal tissues. Several volumetric dosimeters have shown potential in conventional radiotherapy modalities, but suffer from dose under-responding, or signal quenching, in proton therapy. This reduced response has been seen with gels as well as with radiochromic plastics and may result from dependences on dose rate and linear energy transfer (LET). Investigations have shown that the under-response is affected by the chemical concentration of the active components of PRESAGE®, and changes to the composition have been shown to reduce quenching. It is not clear if similar changes can be made to gels. This report reviews studies into the impact of formulation changes on signal quenching, and the degree to which mathematical corrections might still be needed to achieve accurate dosimetry.

  • Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial

    by Jeff M. Michalski, Kathryn A. Winter, Bradley R. Prestidge, Martin G. Sanda, Mahul Amin, William S. Bice, Hiram A. Gay, Geoffrey S. Ibbott, Juanita M. Crook, Charles N. Catton, et al.

    PURPOSE: To determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer.METHODS: Men with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to prostate and seminal vesicles followed by BT prostate boost (110 Gy if 125-Iodine, 100 Gy if 103-Pd). BT arm was delivered to prostate only (145 Gy if 125-Iodine, 125 Gy if 103-Pd). The primary end point was FFP: PSA failure (American Society for Therapeutic Radiology and Oncology [ASTRO] or Phoenix definitions), local failure, distant failure, or death.RESULTS: Five hundred eighty-eight men were randomly assigned; 579 were eligible: 287 and 292 in COMBO and BT arms, respectively. The median age was 67 years; 89.1% had PSA < 10 ng/mL, 89.1% had GS 7, and 66.7% had T1 disease. There were no differences in FFP. The 5-year FFP-ASTRO was 85.6% (95% CI, 81.4 to 89.7) with COMBO compared with 82.7% (95% CI, 78.3 to 87.1) with BT (odds ratio [OR], 0.80; 95% CI, 0.51 to 1.26; Greenwood T P = .18). The 5-year FFP-Phoenix was 88.0% (95% CI, 84.2 to 91.9) with COMBO compared with 85.5% (95% CI, 81.3 to 89.6) with BT (OR, 0.80; 95% CI, 0.49 to 1.30; Greenwood T P = .19). There were no differences in the rates of genitourinary (GU) or GI acute toxicities. The 5-year cumulative incidence for late GU/GI grade 2+ toxicity is 42.8% (95% CI, 37.0 to 48.6) for COMBO compared with 25.8% (95% CI, 20.9 to 31.0) for BT ( P < .0001). The 5-year cumulative incidence for late GU/GI grade 3+ toxicity is 8.2% (95% CI, 5.4 to 11.8) compared with 3.8% (95% CI, 2.0 to 6.5; P = .006).CONCLUSION: Compared with BT, COMBO did not improve FFP for prostate cancer but caused greater toxicity. BT alone can be considered as a standard treatment for men with intermediate-risk prostate cancer.


  • Past AAPM President: 1999

    by Geoffrey S Ibbott

  • Open Access

    Medical physicist certification and training program accreditation

    by Geoffrey S. Ibbott, Arun Chougule, John Damilakis, Slavik Tabakov, Raymond K. Wu, Colin G. Orton, Tomas Kron

    As a profession, medical physics combines an advanced understanding of physics and math with knowledge of biology, anatomy and physiology. Consequently, rigorous education and training is required to assure that medical physicists have the requisite fundamental knowledge, specialized technical skills, and clinical understanding to contribute to the medical care of patients safely. There is, therefore, an interest in standardizing the educational pathways and in developing mechanisms to assure that competency is achieved and maintained. Throughout the world, several countries, regions, and professional organizations have developed mechanisms for accrediting medical physics educational programs, both for didactic work performed in undergraduate or post-graduate settings, and for clinical training conducted in hospitals and clinics. In addition, several national and international programs exist for certifying individual medical physicists. In some cases, once initial certification is achieved, the diplomate enters a program of maintenance of certification, to ensure that the skills obtained during training are not lost over a career. This article explores the differences and similarities in the training program accreditation and physicist certification mechanisms.


  • Low-density gel dosimeter for measurement of the electron return effect in an MR-linac

    by Brigid A McDonald, Hannah Jungeun Lee, Geoffrey S Ibbott

    Radiation therapy in the presence of a strong magnetic field is known to cause regions of enhanced and reduced dose at interfaces of materials with varying densities, in a phenomenon known as the electron return effect (ERE). In this study, a novel low-density gel dosimeter was developed to simulate lung tissue and was used to measure the ERE at the lung-soft tissue interface. Low-density gel dosimeters were developed with Fricke xylenol orange gelatin (FXG) and ferrous oxide xylenol orange (FOX) gels mixed with polystyrene foam beads of various sizes. The gels were characterized based on CT number, MR signal intensity, and uniformity. All low-density gels had CT numbers roughly equivalent to lung tissue. The optimal lung-equivalent gel formulation was determined to be FXG with <1 mm polystyrene beads due to the higher signal intensity of FXG compared to FOX and the higher uniformity with the small beads. Dose response curves were generated for the optimal low-density gel and conventional FXG. The change in spin-lattice relaxation rate (R1) before and after irradiation was linear with dose for both gels. Next, phantoms consisting of concentric cylinders with low-density and conventional FXG were created to simulate the lung-soft tissue interface. The phantoms were irradiated in a conventional linear accelerator (linac) and in a linac combined with a 1.5 T magnetic resonance imaging (MRI) unit (MR-linac) to measure the effects of the magnetic field on the dose distribution. Hot and cold spots were observed in the dose distribution at the boundaries between the gels for the phantom irradiated in the MR-linac but not the conventional linac, consistent with the ERE.


  • Development of a flattening filter free multiple source model for use as an independent, Monte Carlo, dose calculation, quality assurance tool for clinical trials

    by Austin M. Faught, Scott. E. Davidson, Richard Popple, Stephen F. Kry, Carol Etzel, Geoffrey S. Ibbott, David S. Followill

    The Imaging and Radiation Oncology Core‐Houston (IROC‐H) Quality Assurance Center (formerly the Radiological Physics Center) has reported varying levels of compliance from their anthropomorphic phantom auditing program. IROC‐H studies have suggested that one source of disagreement between institution submitted calculated doses and measurement is the accuracy of the institution's treatment planning system dose calculations and heterogeneity corrections used. In order to audit this step of the radiation therapy treatment process, an independent dose calculation tool is needed. Monte Carlo multiple source models for Varian flattening filter free (FFF) 6 MV and FFF 10 MV therapeutic x‐ray beams were commissioned based on central axis depth dose data from a 10 × 10 cm2 field size and dose profiles for a 40 × 40 cm2 field size. The models were validated against open‐field measurements in a water tank for field sizes ranging from 3 × 3 cm2 to 40 × 40 cm2. The models were then benchmarked against IROC‐H's anthropomorphic head and neck phantom and lung phantom measurements. Validation results, assessed with a ±2%/2 mm gamma criterion, showed average agreement of 99.9% and 99.0% for central axis depth dose data for FFF 6 MV and FFF 10 MV models, respectively. Dose profile agreement using the same evaluation technique averaged 97.8% and 97.9% for the respective models. Phantom benchmarking comparisons were evaluated with a ±3%/2 mm gamma criterion, and agreement averaged 90.1% and 90.8% for the respective models. Multiple source models for Varian FFF 6 MV and FFF 10 MV beams have been developed, validated, and benchmarked for inclusion in an independent dose calculation quality assurance tool for use in clinical trial audits.